Core Viewpoint - Jincheng Pharmaceutical reported a significant decline in both revenue and net profit for the first half of 2025, indicating challenges in its business performance [1]. Financial Performance - The company achieved a revenue of 1.36 billion yuan, a decrease of 22.65% compared to the same period last year [2]. - The net profit attributable to shareholders was 43.38 million yuan, down 66.78% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 38.73 million yuan, reflecting a decline of 68.12% [2]. - The net cash flow from operating activities was 104.37 million yuan, a decrease of 40.34% compared to the previous year [2]. - Basic and diluted earnings per share were both 0.11 yuan, down 67.65% from 0.34 yuan [2]. - The weighted average return on equity was 1.16%, down from 3.50% [2]. Asset and Equity Position - Total assets at the end of the reporting period were 5.28 billion yuan, a decrease of 5.74% from the end of the previous year [2]. - The net assets attributable to shareholders were 3.70 billion yuan, down 1.84% from the previous year-end [2]. Segment Performance - Revenue from the cephalosporin side chain active ester series products decreased by 32.20%, with a gross margin of 29.86%, down 4.35% [3]. - Revenue from the biopharmaceutical and specialty raw material series products increased by 10.12%, with a gross margin of 45.99%, down 5.41% [3]. - Revenue from formulation products decreased by 29.04%, with a gross margin of 50.19%, down 6.59% [3]. - Revenue from other pharmaceutical chemical products decreased by 19.12%, with a gross margin of 16.74%, down 1.20% [3].

Core Viewpoint - Jincheng Pharmaceutical (300233) reported a significant decline in both revenue and net profit for the first half of 2025, indicating challenges in its business performance [1][2]. Financial Performance - The company achieved a revenue of 1.36 billion yuan, a decrease of 22.65% compared to the same period last year [2]. - The net profit attributable to shareholders was 43.38 million yuan, down 66.78% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 38.73 million yuan, reflecting a decline of 68.12% [2]. - The net cash flow from operating activities was 104.37 million yuan, a decrease of 40.34% compared to the previous year [2]. - Basic and diluted earnings per share were both 0.11 yuan, down 67.65% from 0.34 yuan [2]. - The weighted average return on equity was 1.16%, down from 3.50% [2]. Asset and Equity Position - Total assets at the end of the reporting period were 5.28 billion yuan, a decrease of 5.74% from the end of the previous year [2]. - The net assets attributable to shareholders were 3.70 billion yuan, down 1.84% from the previous year-end [2]. Segment Performance - Revenue from the bio-pharmaceutical and specialty raw material series products showed positive growth, while revenue from cephalosporin side-chain active ester series products, formulation products, and other pharmaceutical chemical products declined compared to the previous year [2]. - The gross profit margin for all four major product segments decreased during the first half of the year [2]. Product-Specific Insights - Revenue from cephalosporin side-chain active esters was 297.60 million yuan, down 32.20% year-on-year, with a gross margin of 29.86%, a decrease of 4.35% [3]. - Revenue from bio-pharmaceutical and specialty raw material series products was 230.20 million yuan, up 10.12%, with a gross margin of 45.99%, down 5.41% [3]. - Revenue from formulation products was 470.46 million yuan, down 29.04%, with a gross margin of 50.19%, down 6.59% [3]. - Revenue from other pharmaceutical chemical products was 361.99 million yuan, down 19.12%, with a gross margin of 16.74%, down 1.20% [3].

证券代码：300233 证券简称：金城医药 公告编号：2025-057 山东金城医药集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）于2025年8月19日召 开第六届董事会第十六次会议和第六届监事会第十三次会议，分别审议通过 《2025年半年度利润分配方案》，现将有关情况公告如下： 一、公司利润分配方案的基本情况 根据公司 2025 年半年度未经审计的财务报告，截止 2025 年 6 月 30 日，公 司合并报表可供股东分配的利润为 834,426,708.43 元，母公司可供股东分配的 利润为 353,586,400.58 元。根据利润分配应以母公司的可供分配利润及合并报 表的可供分配利润孰低原则，公司 2025 年半年度可供股东分配的利润为 根据有关规定，上市公司回购专用账户中的股份不享有利润分配的权利，因 此，公司回购专用证券账户中的股份将不参与公司本次利润分配。 公司 2025 年半年度利润分配方案为：公司拟以截至 2025 年 6 月 30 日公司 总股本 383,874,587 股扣 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-061 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以2025年6月30日公司总股本383,874,587股扣除回购专 用账户中4,543,000股后的379,331,587股为基数，向全体股东每10股派发现金红利1.00元（含税），送红 股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 □适用 √不适 ...

Core Viewpoint - Jin Cheng Pharmaceutical announced a semi-annual distribution plan for 2025, proposing a cash dividend of 1 yuan per 10 shares (including tax), totaling approximately 37.93 million yuan, which represents 87.44% of the company's net profit [2]. Financial Performance - The company reported a revenue of 1.36 billion yuan for the first half of 2025, a year-on-year decrease of 22.65% - The net profit for the same period was 43.38 million yuan, down 66.78% year-on-year, with basic earnings per share of 0.11 yuan [2]. Dividend History - This marks the 17th cumulative cash distribution since the company's listing - The latest distribution plan is consistent with previous distributions, with varying amounts and dividend yields over the years [2]. Industry Comparison - In the pharmaceutical and biotechnology sector, 17 companies announced their semi-annual distribution plans for 2025 - WuXi AppTec led the sector with a cash distribution of 1 billion yuan, followed by China Resources Sanjiu and Baiyunshan with distributions of 751.31 million yuan and 650.32 million yuan, respectively [4].

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 1.36 billion yuan, a year-on-year decrease of 22.65% [1] - The net profit attributable to shareholders was 43.38 million yuan, reflecting a year-on-year decline of 66.78% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 38.73 million yuan, down 68.12% year-on-year [1] - Basic earnings per share were reported at 0.11 yuan [1]

格隆汇8月20日丨金城医药（维权）(300233.SZ)公布半年度报告，2025年上半年，随着医保及各级集采 等一系列医改政策的不断推进，公司采取多种措施积极应对市场变化和竞争压力，推动公司稳步发展。 报告期，公司生物制药业务保持平稳；头孢侧链医药中间体及头孢粉针注射剂市场竞争加剧，部分产品 销量及价格有不同程度的下降。报告期，公司实现营业收入13.60亿元，同比下降22.65%；实现归属于 上市公司股东的净利润4,338.32万元，同比下降66.78%。向全体股东每10股派发现金红利1.00元。 ...

Core Viewpoint - Jincheng Pharmaceutical (300233) reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in its business operations and market conditions [1][2]. Financial Performance - The company achieved operating revenue of 1.36 billion yuan, a year-on-year decrease of 22.65% [2]. - The net profit attributable to shareholders was 43.38 million yuan, down 66.78% compared to the previous year [2]. - The net profit after deducting non-recurring gains and losses was 38.73 million yuan, reflecting a decline of 68.12% [2]. - The net cash flow from operating activities was 104.37 million yuan, a decrease of 40.34% [2]. - Basic and diluted earnings per share were both 0.11 yuan, down 67.65% year-on-year [2]. - The weighted average return on equity was 1.16%, down from 3.50% [2]. - Total assets at the end of the reporting period were 5.28 billion yuan, a decrease of 5.74% from the previous year [2]. - The net assets attributable to shareholders were 3.70 billion yuan, down 1.84% [2]. Business Operations - The company has been focusing on five strategic areas: pharmaceutical chemicals, synthetic biology, women's health technology, high-end anti-infection, and new tobacco [2]. - Key products include cephalosporin side-chain active esters, biopharmaceuticals, specialty APIs, and other pharmaceutical chemical products [2]. - The biopharmaceutical business remained stable, while competition in the cephalosporin intermediate and injection markets intensified, leading to declines in sales and prices for some products [3]. - Sales expenses decreased by 42.33%, primarily due to reduced marketing and maintenance costs [3]. Historical Performance - The company's financial performance has been unstable, with a loss of 489 million yuan in 2020, followed by two years of stability, and a net profit decline of over 36% in 2023 [3]. - In 2024, net profit rebounded by 12.63%, but revenue still fell by 4.66% [3]. Regulatory Issues - The company's actual controller and chairman, Zhao Yeqing, is facing regulatory scrutiny from the China Securities Regulatory Commission (CSRC) for alleged market manipulation, which may result in a four-year market ban [5][6]. - Zhao Yeqing has been the chairman since February 16, 2011, and is implicated in violations of the Securities Law, with proposed penalties including the confiscation of illegal gains and fines totaling over 46 million yuan [5][6].

Core Viewpoint - Jincheng Pharmaceutical reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business operations and market conditions [2]. Financial Performance - The company's revenue for the first half of 2025 was approximately 1.36 billion yuan, representing a year-on-year decrease of 22.65% [2]. - The net profit attributable to shareholders was around 43.38 million yuan, down 66.78% compared to the previous year [2]. - Basic earnings per share were reported at 0.11 yuan, reflecting a decrease of 67.65% year-on-year [2].

山东金城医药集团股份有限公司 董事会战略委员会工作细则 第五条 战略委员会设主任委员（召集人）一名，由公司董事长担任，负责 召集和主持战略委员会的工作。如董事长并非战略委员会委员，则主任委员由董 事会过半数选举产生和罢免。 第六条 战略委员会委员必须符合有关法律、行政法规、规范性文件及《公 司章程》规定的董事任职条件。 山东金城医药集团股份有限公司 董事会战略委员会工作细则 第一章 总 则 第一条 为使山东金城医药集团股份有限公司（以下简称"公司"）董事会 战略委员会工作规范化、制度化，提高工作效率、工作质量，根据《中华人民共 和国公司法》《上市公司治理准则》《上市公司独立董事管理办法》等相关法律、 行政法规、规范性文件及《山东金城医药集团股份有限公司章程》（以下简称"《公 司章程》"）、《山东金城医药集团股份有限公司独立董事制度》（以下简称"《独 立董事制度》"）的规定，结合公司实际情况，制定本工作细则。 第二条 董事会战略委员会（以下称"战略委员会"）是董事会下设的专门 委员会，主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。战 略委员会对董事会负责，向董事会报告工作。 第二章 人员组成 第三 ...